High expression of crystallin αB represents an independent molecular marker for unfavourable ovarian cancer patient outcome and impairs TRAIL- and cisplatin-induced apoptosis in human ovarian cancer cells

Implementing an online tool for genome-wide validation of survival-associated biomarkers in ovarian-cancer using microarray data from 1287 patients

(2012) Balázs Győrffy et al.   ENDOCRINE-RELATED CANCER

Drug-induced caspase 8 upregulation sensitises cisplatin-resistant ovarian carcinoma cells to rhTRAIL-induced apoptosis

(2011) E W Duiker et al.   BRITISH JOURNAL OF CANCER

Cancer Statistics, 2010

(2010) A. Jemal et al.   CA-A CANCER JOURNAL FOR CLINICIANS

Too Much of a Good Thing: Suicide Prevention Promotes Chemoresistance in Ovarian Carcinoma

(2010) K. Pennington et al.   CURRENT CANCER DRUG TARGETS

Overcoming TRAIL resistance in ovarian carcinoma

(2010) Kerri S. Bevis et al.   GYNECOLOGIC ONCOLOGY

Check your cultures! A list of cross-contaminated or misidentified cell lines

(2010) Amanda Capes-Davis et al.   INTERNATIONAL JOURNAL OF CANCER

The inhibition of Bid expression by Akt leads to resistance to TRAIL-induced apoptosis in ovarian cancer cells

(2010) N Goncharenko-Khaider et al.   ONCOGENE

Ovarian cancer ascites protects from TRAIL-induced cell death through αvβ5 integrin-mediated focal adhesion kinase and Akt activation

(2010) D Lane et al.   ONCOGENE

The prosurvival activity of ascites against TRAIL is associated with a shorter disease-free interval in patients with ovarian cancer

(2010) Denis Lane et al.   Journal of Ovarian Research

Is TRAIL the holy grail of cancer therapy?

(2009) Thomas Newsom-Davis et al.   APOPTOSIS

Enhanced Antitumor Efficacy of a DR5-Specific TRAIL Variant over Recombinant Human TRAIL in a Bioluminescent Ovarian Cancer Xenograft Model

(2009) E. W. Duiker et al.   CLINICAL CANCER RESEARCH

Integrin αvβ3 upregulates integrin-linked kinase expression in human ovarian cancer cells via enhancement of ILK gene transcription

(2009) Daniela Lössner et al.   JOURNAL OF CELLULAR PHYSIOLOGY

Gene knockdown studies revealed CCDC50 as a candidate gene in mantle cell lymphoma and chronic lymphocytic leukemia

(2009) A Farfsing et al.   LEUKEMIA

A Phase 1 Study of Mapatumumab (Fully Human Monoclonal Antibody to TRAIL-R1) in Patients with Advanced Solid Malignancies

(2008) S. J. Hotte et al.   CLINICAL CANCER RESEARCH